Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150747 · ClinicalTrials.gov registry record
Chlamydia Trachomatis Immunology and Vaccinology Study
A clinical trial, sponsored by Harold Wiesenfeld.
- Completed
- Registry status
- 347
- Enrollment target
NCT01150747 is a clinical trial that has completed, run by Harold Wiesenfeld. The registered enrollment target is 347 participants.
The verdict
NCT01150747 has completed, sponsored by Harold Wiesenfeld.
- COMPLETED
- Registry status
- 347 participants
- Enrollment target
Study Summary
The primary objective is to prospectively follow 200 women with or at risk of cervicitis to determine the chlamydia-specific cellular responses that correlate with protection against incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T cells responding to stimulation with HSP60 will be significantly associated with protection from incident C. trachomatis infection.
Interventions
- DRUG Azithromycin
- DRUG ceftriaxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150747
The ClinicalTrials.gov registry entry for NCT01150747 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harold Wiesenfeld, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azithromycin is the first listed.
NCT01150747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150747 about?
NCT01150747 is a clinical study titled "Chlamydia Trachomatis Immunology and Vaccinology Study". The primary objective is to prospectively follow 200 women with or at risk of cervicitis to determine the chlamydia-specific cellular responses that correlate with protection against incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T cells responding to stimula...
What is the current status of trial NCT01150747?
This trial is currently completed. The enrollment target is 347 participants. The study started on 2011-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01150747?
The interventions under investigation include: Azithromycin (DRUG), ceftriaxone (DRUG).
Who is sponsoring clinical trial NCT01150747?
This trial is sponsored by Harold Wiesenfeld, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.